anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND/AIM: Recently, the prognostic immune and nutritional index (PINI) was developed and reported to be a promising nutritional and inflammatory prognostic marker. The aim of the present study was to clarify the clinical impact of the PINI for esophageal cancer patients who received curative treatment.
PATIENTS AND METHODS: We conducted a retrospective review of medical records and collected data on consecutive esophageal cancer patients who underwent curative resection at Yokohama City University between 2005 and 2020. The PINI was calculated by dividing the serum ALB concentration (g/dl) by the serum monocyte concentration, both of which were measured before surgery.
RESULTS: A total of 180 patients were included in this study. The cutoff value of the PINI was 3.0 in the present study. The 3- and 5-year overall survival rates were 45.2% and 33.5%, respectively, in the PINI-low subgroup, and 69.1% and 61.8%, respectively, in the PINI-high subgroup. A multivariate analysis demonstrated that the PINI was an independent prognostic factor for overall survival (hazard ratio=2.091, 95% confidence interval=1.287-3.399, p=0.003). Similar results were observed for recurrence-free survival. When comparing the sites of recurrence between the two groups, the incidence of hematological recurrence was significantly greater in the PINI-low subgroup compared to the PINI-high subgroup (46.8% vs. 21.1%, p<0.001).
CONCLUSION: The PINI is a promising nutritional and inflammatory marker for esophageal cancer patients. The PINI might be a useful marker for the treatment and management of esophageal cancer patients.
PURPOSE:To provide the titled novel polymer compound suitable as a remedy for  hyperlipemia, by coordinating a polyvalent metallic ion to a crosslinked polymer derived from polyethylene polyamine, polyethyleneimine, and a bifunctional compound, and  quaternizing the N atom. CONSTITUTION:(A) A polyethylene polyamine having a recurrence degree of 2-10 and  an average molecular weight of 103-477 or a polyethyleneimine having a recurrence  degree of 930-1,163 and an average molecular weight of 40,000-500,000 is made to  react with (B) a bifunctional compound of formulaI [Y is CH2X, group of formula  II (X is Cl, Br or I) or formula III; A is single bond, (CH2)m (m is 1-3), group of  formula IV or formula V (k is 1-4); Z is same as Y] (e.g. epichlorohydrin) to obtain  a crosslinked polymer, which is coordinated with polyvalent metallic ions (e.g. Fe, Al,  etc.). The resultant metal-crosslinked polymer is treated with a tertiarizing agent (e.g.  formic acid-formaldehyde) and then with a quaternizing agent (e.g. allyl bromide) until  20-80% of the N atoms are converted to guaternary N atoms. If necessary, the product is converted to a pharmacologically premissible salt.
Patients in this arm will receive PD G 506 A orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence imaging performed after SoC BCS is complete will guide the resection of additional tissue.
NEW MATERIAL:A compound of formula I (B is H, formula II; X1-X3 are H, hydroxyl, methoxy; Y is O, NH; Z is methyl, phenyl; R is 3-18C alkyl, cyclohexyl, trimethylcyclohexyl). EXAMPLE:N-Benzoyl-O-methyl-alpha-dehydrotyrosine laurylamide. USE:An ultraviolet absorber. It is used to prevent skin erythema and deterioration prevention for resins. It is used over wide ranges of fields such as cosmetics, plastics, organic chemicals, photography, food and fibers. PREPARATION:The condensation reaction between an aromatic aldehyde of formula III and acetylglycine, benzoylglycine or azulactone thereof is conducted in the presence of a base to form an azulactone. The reaction is followed by hydrolysis, esterification, or amidization, direct alcoholysis of azulactone and aminolysis to give the compound of formula I.
The objective of this review is to study the relationship between food insecurity (FI) and malnutrition in schoolchildren from low-and middle-income countries (LMIC). The review was conducted using the databases PubMed, MEDLINE, CENTRAL, LILACS and SCiELO during the months of March to April 2022 without language or publication date restrictions. The search strategy consisted of combinations of text words and controlled vocabulary (MeSH terms and DeCS) related to "schoolchildren", "low- and middle-income countries" and "food insecurity". Fifteen studies were included in this review. Studies assessing FI and undernutrition in LMIC schoolchildren have indicated that FI is associated with lower height-for-age and higher prevalence of undernutrition overall. Only two studies identified a positive risk association between FI and overweight and obesity, the remaining studies suggested that schoolchildren with FI have a lower risk of overweight and obesity than those without FI. The review suggests a link between FI and undernutrition in schoolchildren from LMIC, with controversial results on overweight and obesity. Comprehensive public health policies should consider contextual and population-specific factors in addressing FI's impact on nutritional status.
The invention provides a nano-drug carrier, which has a structure of a double-stranded framework nucleic acid tetrahedron, wherein each arm of the tetrahedron consists of two DNA double helices and comprises DNA single strand sequences SEQ ID NO. 1-25. The invention also provides a nano-drug prepared from the nano-drug carrier and application thereof in killing tumor and bacteria in the tumor. The nano-drug carrier provided by the invention has higher drug loading capacity and targeting of bacteria in tumors. The nano-drug provided by the invention can identify and combine bacteria in tumor, directly kill bacteria, exert the effect of inhibiting tumor cells and regulate the immune microenvironment of tumor. The nano-drug provided by the invention has the advantages of controllable morphology rule, good biological safety, high bactericidal activity and certain immunoregulation effect, can effectively inhibit tumor growth, and has a good application prospect.
Blood amino acid levels are maintained in a narrow physiological range. The pancreatic α cells have emerged as the primary aminoacidemia regulator through glucagon secretion to promote hepatic amino acid catabolism. Interruption of glucagon signaling disrupts the liver-α cells axis leading to hyperaminoacidemia, which triggers a compensatory rise in glucagon secretion and α cell hyperplasia. The mechanisms of hyperaminoacidemia-induced α cell hyperplasia remain incompletely understood. Using a mouse α cell line and in vivo studies in zebrafish and mice, we found that hyperaminoacidemia-induced α cell hyperplasia requires ErbB3 signaling. In addition to mechanistic target of rapamycin complex 1, another ErbB3 downstream effector signal transducer and activator of transcription 3 also plays a role in α cell hyperplasia. Mechanistically, ErbB3 may partner with ErbB2 to stimulate cyclin D2 and suppress p27 via mechanistic target of rapamycin complex 1 and signal transducer and activator of transcription 3. Our study identifies ErbB3 as a new regulator for hyperaminoacidemia-induced α cell proliferation and a critical component of the liver-α cells axis that regulates aminoacidemia.
Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content. Additionally, participants receive the Text Message Booster Component in the days before and during the high risk drinking event celebration(s).
BACKGROUND: Hospital-onset bacteraemia and fungaemia (HOB) is being explored as a surveillance and quality metric. The objectives of the current study were to determine sources and preventability of HOB in hospitalised patients in the USA and to identify factors associated with perceived preventability.
METHODS: We conducted a cross-sectional study of HOB events at 10 academic and three community hospitals using structured chart review. HOB was defined as a blood culture on or after hospital day 4 with growth of one or more bacterial or fungal organisms. HOB events were stratified by commensal and non-commensal organisms. Medical resident physicians, infectious disease fellows or infection preventionists reviewed charts to determine HOB source, and infectious disease physicians with training in infection prevention/hospital epidemiology rated preventability from 1 to 6 (1=definitely preventable to 6=definitely not preventable) using a structured guide. Ratings of 1-3 were collectively considered 'potentially preventable' and 4-6 'potentially not preventable'.
RESULTS: Among 1789 HOB events with non-commensal organisms, gastrointestinal (including neutropenic translocation) (35%) and endovascular (32%) were the most common sources. Overall, 636/1789 (36%) non-commensal and 238/320 (74%) commensal HOB events were rated potentially preventable. In logistic regression analysis among non-commensal HOB events, events attributed to intravascular catheter-related infection, indwelling urinary catheter-related infection and surgical site infection had higher odds of being rated preventable while events with neutropenia, immunosuppression, gastrointestinal sources, polymicrobial cultures and previous positive blood culture in the same admission had lower odds of being rated preventable, compared with events without those attributes. Of 636 potentially preventable non-commensal HOB events, 47% were endovascular in origin, followed by gastrointestinal, respiratory and urinary sources; approximately 40% of those events would not be captured through existing healthcare-associated infection surveillance.
DISCUSSION: Factors identified as associated with higher or lower preventability should be used to guide inclusion, exclusion and risk adjustment for an HOB-related quality metric.
Subjects will receive at least 4 cycles of standard adjuvant therapy according to CSCO clinical guidelines after surgery. Then subjects will receive iNeo-Vac-R01 via IH injection on Day 1 of each 21-day cycle for up to 9 cycles at an applicable dose, identified during the dose escalation phase of the study.
Chronic sinusitis is one of the most prevalent chronic illnesses in the United States and a significant health concern in terms of public health care expenditure. We wish to learn more about pathogenic factors causing or contributing to chronic sinusitis. One of these factors is secondhand smoke (SS) exposure. However, several other factors are involved, including allergic, environmental, genetic and microbiologic factors and in any given patient, several of these factors may be contributing to the disease. One of our goals is to see whether specific patterns of inflammatory cells, cytokines or chemokines exist that can differentiate these causative factors and to help us to better understand their individual contributions to the disease.

Several inflammatory cells, cytokines and chemokines are present in chronically inflamed sinus tissue, and we believe they form the basis for the disease process. At present, we know very little about what drives them into the sinus tissues. We believe that the types of inflammatory cells, cytokines and chemokines elicited in this disease depend on the inciting stimulus.

Cigarette smoke has well-documented deleterious effects on respiratory mucosa that could promote the development of chronic sinusitis. These include reduction in normal mucociliary function; increased nasal airway resistance; induction of mucin gene expression and induction of chronic inflammation. In the proposed study, we will extend our previous findings to investigate the relationships between SS exposure and these inflammatory markers and also examine the relationship of these cytokines to the expression of particular mucins.

Extracts of cigarette smoke have been shown to induce numerous other proinflammatory effects on respiratory epithelial cells either in vivo or in vitro. In this study we will analyze the gene expression of inflammatory markers in a nasal mucosal biopsy. Our intent is to study sinusitis rather than rhinitis. Nonetheless, we will examine nasal rather than sinus mucosa largely owing to the difficulties posed by obtaining samples directly from the sinuses. Furthermore, recent consensus reports have emphasized the importance of viewing sinusitis as a continuum of nasal and sinus mucosal inflammation. These same arguments have been put forward in terms of the concept of "one airway, one disease" which has emphasized the commonality of mucosal inflammation seen in the upper airway (rhinitis, sinusitis) and the lower airway (asthma). The biopsies will come from the middle turbinate. The latter structure has the same pseudostratified columnar epithelium and a virtually identical appearance to that of maxillary or ethmoid sinus mucosa. We have used biopsies from the middle turbinate in several previous studies of chronic sinusitis, primarily as a comparative tissue representing "healthy" sinus mucosa.
The invention discloses bacillus sp. and application of bacillus sp. in preparing antibacterial drugs. The preservation number of bacillus sp. No. B1 is CCTCC No. M2013698. The bacillus sp. No. B1 has antagonism to multiple bacteria, so that the bacillus sp. No. B1 can be used for preparing preparation for preventing and controlling hemolysis vibrio; the preparation for preventing and controlling hemolysis vibrio can be used for beneficial microbial preparation to replace chemical medicine, improves water quality, and eliminates hemolysis vibrio in an aquatic product cultivation system, so that damage to aquatic product cultivation objects from hemolysis vibrio is prevented, the development of the aquatic product cultivation industry is promoted, aquatic products are prevented from carrying the hemolysis vibrio, and health and safety of human beings are ensured.
The present invention provides TGF-β3 for use as a medicament for provision to a scar to bring about the non-surgical improvement thereof. The medicaments may preferably be injectable medicaments. The invention also provides corresponding methods of treatment. A suitable amount of TGF-β3 to be provided may be between about 100 ng and 10,000 of TGF-β3 per centimetre of scar to be non-surgically improved, and is preferably about 500 ng or 1000 ng of TGF-β3 per centimetre of scar to be non-surgically improved. The scar to be improved may be a scar of the skin. Scars to be improved may be between 2 and 6 months post-wounding. Improvement using the medicaments or methods of the invention may reduce the redness and/or contrast of the scar.
OBJECTIVE: Ultrasound speckle tracking enables in vivo measurement of soft tissue deformation or strain, providing a non-invasive diagnostic tool to quantify tissue health. However, adoption into new fields is challenging since algorithms need to be tuned with gold-standard reference data that are expensive or impractical to acquire. Here, we present a novel optimization approach that only requires repeated measurements, which can be acquired for new applications where reference data might not be readily available or difficult to get hold of.
METHODS: Soft tissue motion was captured using ultrasound for the medial collateral ligament (MCL) of three quasi-statically loaded porcine stifle joints, and medial ligamentous structures of a dynamically loaded human cadaveric knee joint. Using a training subset, custom speckle tracking algorithms were created for the porcine and human ligaments using surrogate optimization, which aimed to maximize repeatability by minimizing the normalized standard deviation of calculated strain maps for repeat measurements. An unseen test subset was then used to validate the tuned algorithms by comparing the ultrasound strains to digital image correlation (DIC) surface strains (porcine specimens) and length change values of the optically tracked ligament attachments (human specimens).
RESULTS: After 1500 iterations, the optimization routine based on the porcine and human training data converged to similar values of normalized standard deviations of repeat strain maps (porcine: 0.19, human: 0.26). Ultrasound strains calculated for the independent test sets using the tuned algorithms closely matched the DIC measurements for the porcine quasi-static measurements (R > 0.99, RMSE < 0.59%) and the length change between the tracked ligament attachments for the dynamic human dataset (RMSE < 6.28%). Furthermore, strains in the medial ligamentous structures of the human specimen during flexion showed a strong correlation with anterior/posterior position on the ligaments (R > 0.91).
CONCLUSION: Adjusting ultrasound speckle tracking algorithms using an optimization routine based on repeatability led to robust and reliable results with low RMSE for the medial ligamentous structures of the knee. This tool may be equally beneficial in other soft-tissue displacement or strain measurement applications and can assist in the development of novel ultrasonic diagnostic tools to assess soft tissue biomechanics.
A method for treating an addiction disorder (such as an addiction to or dependency on stimulants, nicotine, morphine, heroin, other opiates, amphetamines, cocaine, and/or alcohol) in a patient is disclosed. The method includes administering to the patient a first α3β4 nicotinic receptor antagonist and administering to the patient a second α3β4 nicotinic receptor antagonist. The second α3β4 nicotinic receptor antagonist is different than the first α3β4 nicotinic receptor antagonist and the second α3β4 nicotinic receptor antagonist are administered simultaneously or non-simultaneously. Compositions which include a first α3β4 nicotinic receptor antagonist are also described. Examples of suitable α3β4 nicotinic receptor antagonists for use in the present invention's methods and compositions include mecamylamine, 18-methoxycoronaridine, bupropion, dextromethorphan, dextrorphan, and pharmaceutically acceptable salts and solvates thereof. A method of evaluating a compound for its effectiveness in treating addiction disorders is also described.
Described herein are compositions and methods of use of targeted delivery complexes for delivery of siRNA to a disease-associated cell, tissue or pathogen. The targeted delivery complex comprises a targeting molecule, such as an antibody or fragment thereof, conjugated to one or more siRNA carriers. In preferred embodiments the siRNA carrier is a dendrimer or protamine and the targeting molecule is an anti-cancer antibody, such as hRS7. More preferably, the antibody or fragment is rapidly internalized into the target cell to facilitate uptake of the siRNA. Most preferably, the targeted delivery complex is made by the DNL technique. The compositions and methods are of use to treat a variety of disease states, such as cancer, autoimmune disease, immune dysfunction, cardiac disease, neurologic disease, inflammatory disease or infectious disease.
Participants in the Trial Group will receive a daily intervention consisting of a breakfast that includes one piece of fruits (e.g., an apple or a banana), vegetables (e.g., a carrot or a cucumber), and other regular diet. The fruit and vegetable will be provided as part of a standardized breakfast menu designed by nutrition experts. Participants will also receive an extra fruit box once a week at home. This intervention will be administered every morning, seven days a week, for a duration of 12 weeks. The goal is to increase the daily intake of fruits and vegetables among participants to assess the effects on cognitive performance, mood and attention.
The invention comprises a main body storage box mechanism, a control mechanism, a platform moving mechanism and a piston medicine discharging mechanism. The piston medicine discharging mechanism is fixed inside the main body mechanism, and the platform moving mechanism is fixed at the rear plate of the main body mechanism. Go out the cooperation between medicine mechanism and the platform moving mechanism through the piston for the medicine can go out the medicine according to kind and quantity, and control mechanism controls all the other mechanisms respectively, receives the signal that bluetooth or display screen received through the singlechip and controls motor and all the other sensors, realizes that intelligence goes out the medicine and intelligence is reminded. When the medicine box is used for reminding taking the medicine and discharging the medicine according to the amount, the medicine box can also be subjected to internal sterilization treatment, so that the cleanness of the medicine is ensured. The medicine box is internally provided with an ultraviolet lamp, and the control structure can directly control the ultraviolet lamp to sterilize. The intelligent medicine box device can well solve the problem that the old people take medicines, is high in feasibility, is suitable for batch production, and has good social and economic benefits.
The invention discloses a Chinese medicinal composition for assisting in decreasing blood sugar and a preparation method thereof. The composition is prepared from medicinal materials of panaxadiol saponins, astragalus, large-head atractylodes rhizome, epimedium herb, malaytea scurfpea fruit, south dodder seed, dried ginger, oriental waterplantain rhizome, Indian buead, dogwood and the like as raw materials. The invention further provides a preparation method of the Chinese medicinal composition for assisting in decreasing blood sugar. By using the composition provided by the invention, the fasting blood sugar of a rat with high blood sugar due to mesoxyalyurea can be lowered effectively, and the sugar tolerance can be well regulated. Compared with a control sample group, the Chinese medicinal composition is remarkably lower in fasting blood sugar and remarkably superior in sugar tolerance regulating effect. Experiment results show that the Chinese medicinal composition has a better blood sugar degreasing effect than the conventional traditional Chinese medicine, and is high in safety and free from side effects.
The usual care group will not be given an Owlet vital sign monitor. Will complete a survey or questionnaire every month until 6 months after discharge.
Fat is stored in distinct depots with unique features in both mice and humans and B cells reside in all adipose depots. We have shown that B cells modulate cardiometabolic disease through activities in two of these key adipose depots: visceral adipose tissue (VAT) and perivascular adipose tissue (PVAT). VAT refers to the adipose tissue surrounding organs, within the abdomen and thorax, and is comprised predominantly of white adipocytes. This depot has been implicated in mediating obesity-related dysmetabolism. PVAT refers to adipose tissue surrounding major arteries. It had long been thought to exist to provide protection and insulation for the vessel, yet recent work demonstrates an important role for PVAT in harboring immune cells, promoting their function and regulating the biology of the underlying vessel. The role of B-2 cells and adaptive immunity in adipose tissue biology has been nicely reviewed elsewhere. Given that, the predominance of B-1 cells in adipose tissue at homeostasis, and the emerging role of B-1 cells in a variety of disease states, we will focus this review on how B-1 cells function in VAT and PVAT depots to promote homeostasis and limit inflammation linked to cardiometabolic disease and factors that regulate this function.
SHAM group. The participants will receive the same dosage and technique of corticosteroid posterior GHJ and SASD bursa injection for 2 times at 2 weekly interval as participants do in the ESWT group. For creating a single-blinded condition, they will also receive 4 ESWT treatments at weekly interval except that the energy flux density is set at 0.04 mJ/mm2. For sham ESWT, the machine still makes a noise with every shock wave delivered in order to enhance the sham design.